Background Hereditary haemochromatosis (HH) is a common genetic condition amongst people of northern European heritage. HH is associated with increased iron absorption leading to parenchymal organ damage and multiple arthropathies. Early diagnosis and treatment prevents complications. Population screening may increase early diagnosis, but no programmes have been introduced internationally: a paucity of health economic data is often cited as a barrier. Objective To conduct a systematic review of all health economic studies in HH. Methods Studies were identified through electronic searching of economic/biomedical databases. Any study on HH with original economic component was included. Study quality was formally assessed. Health economic data were extracted and analysed through narrative synthesis. Results Thirty-eight studies met the inclusion criteria. The majority of papers reported on costs or cost effectiveness of screening programmes. Whilst most concluded screening was cost effective compared with no screening, methodological flaws limit the quality of these findings. Assumptions regarding clinical penetrance, effectiveness of screening, health-state utility values (HSUVs), exclusion of early symptomatology (such as fatigue, lethargy and multiple arthropathies) and quantification of costs associated with HH were identified as key limitations. Treatment studies concluded therapeutic venepuncture was the most cost-effective intervention. Conclusions There is a paucity of high-quality health economic studies relating to HH. The development of a comprehensive HH cost-effectiveness model utilising HSUVs is required to determine whether screening is worthwhile.
Introduction
Hereditary haemochromatosis (HH) is an autosomal recessive disorder characterised by increased iron absorption. It is one of the most common genetic disorders amongst people of northern European ancestry [1] [2] [3] . A defect in the HFE gene has been found to be the predominant cause of HH with several mutations identified: C282Y, H63D and S56C [4] [5] [6] . Between 80 and 90 % of people diagnosed with iron overload related to HH have been found to be homozygous for the C282Y mutation [7, 8] . The H63D and S56C mutations are less commonly associated with iron overload or related disease unless present with the C282Y mutation, i.e. a compound heterozygote [9, 10] . Prevalence of C282Y homozygosity is highest amongst people of northern European ancestry with a prevalence of approximately 1 in 150-200, whilst in people of other ancestries it is considerably lower: 1 in 300 Hispanics; 1 in 1000 Native Americans; 1 in 1,000,000 Asians [10] [11] [12] [13] [14] . Amongst people of northern European ancestry, the prevalence of C282Y/H63D heterozygotes is relatively common, being found in approximately 1 in 50 people, i.e. four times as common than the C282Y homozygote, whilst C282Y/S56C heterozygote prevalence is approximately 1 in 200, i.e. as common as the C282Y homozygote [5, 15] . In turn, a much smaller proportion of these compound heterozygotes will develop iron overload as compared with the C282Y homozygotes.
Clinically, HH is characterised by increased serum iron and iron stores [2, 16, 17] . The excess iron is stored in the parenchymal tissues of the liver, heart and pancreas. Early symptoms of HH-related iron overload include fatigue, lethargy, loss of appetite and joint pain, most commonly in the fingers [18, 19] . Subsequent symptoms may include multiple arthropathies, type 2 diabetes, impotence, fibrosis, cirrhosis and carcinoma of the liver, and heart disease [20] [21] [22] [23] [24] . The rate of clinical penetrance of HH has been somewhat controversial in the literature. This is in large part due to different definitions of penetrance: some authors have defined HH penetrance as liver cirrhosis, whilst others have included elevated iron studies through to cirrhosis and hepatocellular carcinoma. Recent epidemiological literature has reported penetrance (defined as early symptoms through to irreversible organ damage) of C282Y homozygosity to be 28.4 % for males and 1.2 % for females [11] .
HH is currently diagnosed through targeted and/or opportunistic iron studies, most commonly transferrin saturation (TfS) and serum ferritin (SF) (phenotyping). If TfS and SF are found to be elevated, in the absence of other contributing factors HH is suspected and a genetic test may be ordered (genotyping) [15, 25] . Treatment is effective and straightforward, consisting of regular therapeutic venepuncture (TV). If this is contraindicated, erythrocytapheresis is an alternative treatment in which red blood cells are separated from whole blood via apheresis [26] .
Due to the non-specific nature of the early symptoms of iron overload (in that they can be experienced by people with iron levels within the clinically normal range), diagnosis is often delayed until after irreversible organ damage has occurred [27, 28] . Population screening programmes have been suggested as a way to reduce the burden of disease associated with HH [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . There are several options for HH screening, varying with regard to whom should be screened: whole populations or sub-populations at greatest risk; and how they should be screened: genotyping and/or phenotyping.
The effectiveness of large scale screening for HH involves three main parameters: uptake of screening; sensitivity and specificity of screening tests; and adherence to treatment. Studies reporting on uptake of HH screening have been conducted in a wide range of settings with differing populations and screening techniques. Just one randomised, controlled trial (RCT) has been conducted, which involved random allocation of UK-based general practice patients to either phenotype or genotype screening [39] . In this study an uptake rate of 32 % was reported. A pilot screening programme in Australian schools reported an uptake rate of 33 % [40] , whilst a second Australian study investigating workplace screening reported 5.8 % uptake [41] . In contrast to these studies, a large study in a Norwegian county which invited all inhabitants aged over 20 years of age to be screened for HH in combination with other conditions reported an uptake rate of 70 % [42] .
The sensitivity and specificity of biochemical tests for HH iron overload depend on the cut-off points used. The HEIRS (Hemochromatosis and Iron Overload Screening) study, which involved screening almost 100,000 participants for HH, concluded that TfS, a commonly used diagnostic test, has a low sensitivity and is highly biologically variable, thereby limiting its utility as a screening tool [43] . The authors also noted that whilst SF increases with iron overload, several other factors can also cause elevated SF levels, such as fatty liver and alcohol consumption, which decreases its sensitivity as a screening tool [43] . With regard to genotyping for C282Y homozygotes, a systematic review reported sensitivity ranged between 91.3 and 92.4 %, and specificity between 98.8 and 100 % [44] .
Few studies have reported on adherence to HH treatment. In a workplace setting, compliance to treatment (TV) was reported to be 100 % over a 12-month period [45] . However, a longitudinal study following participants over 9 years reported that whilst adherence was high during the early stage of the study (80 %) , it decreased linearly to 33 % in the ninth year [46] .
Early symptoms of iron overload are vague and can be missed by physicians. A delay in diagnosis of HH could lead to end organ damage [27, 28] . Early detection and treatment of HH can improve clinical outcomes of patients with HH and result in normal life expectancy [47] . As such, strategies for early detection can reduce the burden of disease associated with HH. Different approaches have been suggested to increase the rate of early diagnosis, including enhanced training of physicians in combination with cascade screening and population screening. Whilst HH fulfils several of the criteria set out by the World Health Organization for diseases that may warrant population screening programmes [48] , a lack of rigorous health economic evaluations to support efficient resource allocation has been cited as a barrier [29, 30, 41, 49] .
To our knowledge, no comprehensive systematic reviews of health economic studies have been published on all approaches to HH screening programmes or treatment. This study seeks to ascertain what economic evidence is available to support: (a) population or targeted screening for HH; and (b) treatment of HH.
Methods
The systematic review was performed using the Campbell and Cochrane Economics Methods Group (CCEMG) guidelines [50, 51] . Studies that included full or partial economic evaluations relating to HH were included. Full economic evaluations involve a comparison of the costs and consequences of two or more alternative interventions; partial economic evaluations involve examination of costs and/or consequences of either one or more interventions [52] . The target interventions were kept broad, allowing for inclusion of all possible screening and treatment studies. Studies using hypothetical populations in decision models were also included. No limitations on language of publication were included. The only exclusion criteria were the absence of any health economic data reported within the publication or reviews of other work.
Information Sources
Five health economic/economic databases-Centre for Reviews and Dissemination (CRD) including Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database (HTAD) and NHS Economic Evaluation Database (NHSEED), Cost Effectiveness Analysis Registry (CEA Registry), and EconLit-and four biomedical databases-PubMed, Scopus, Embase (including Medline) and the Cochrane Collaboration-were searched in June 2014 using a predefined search strategy as detailed in Table 1 . In addition, hand searching of citations from relevant papers, previous reviews and industry documents was performed. The search strategy comprised an abridged PICO standard (which references the participants, interventions, comparisons and outcomes), Medical Subject Headings (MeSH) terms and economic search filters. Following this initial search, a review of title and abstract was conducted to finalise included studies.
Data Collection Process
Data were extracted on key parameters, including study design, sample size, duration of screening programme, authorship, year of publication, country in which the study was conducted and study characteristics (screening parameters, setting, target group). Health economic metrics such as type of evaluation, year of assessment, currency, perspective, costs assessed, time frame, discount rate, methods for measuring and valuing outcomes, and summary measure of efficiency calculated were recorded. Health economic studies were evaluated using the British Medical Journal Economic Evaluation Working Party (BMJ) checklist [53] . The BMJ checklist consists of 35-items, and a 36th item on generalisability. Each item was given a score: '1' if the item was performed, '0' if it was not and 'N/A' if the item was not applicable to the study. Equal weighting was given to each item. The number of '1' items was summed, and using the number of applicable items as the denominator the proportion was calculated, providing the final score as a percentage [54] . Studies were defined as low (\50 %), moderate (50-75 %) and high quality ([75 %).
Results

Study Selection
A flow diagram of the search strategy is shown in Fig. 1 . The electronic search yielded 2026 studies. Economic databases generated 34 studies (CRD, including DARE, HTAD and NHSEED, n = 28; CEA Registry, n = 4; and EconLit, n = 2), and biomedical databases produced 1992 studies (PubMed, n = 872; Scopus, n = 643; Embase (including Medline), n = 475; and the Cochrane Collaboration, n = 2). After removal of duplicates, 1066 studies were reviewed against the inclusion/exclusion criteria. 1028 papers were excluded following screening of title and abstract. Papers that were excluded were neither partial nor full economic evaluations relating to HH. Thirty-eight studies met the inclusion criteria. Study selection was carried out by BdG and LS and data extraction conducted by BdG.
Characteristics of the Economic Analyses
Study Characteristics
Characteristics of the studies are presented in brief in Table 2 (and in detail in the appendix), grouped by intervention and methodological quality. Scores derived from the BMJ checklist are included in Table 2 ; however, these should be interpreted with caution. The checklist is designed for authors to ensure they adhere to methodological requirements; it is not ideally suited to scoring the robustness of the results of those papers. For example, with regard to the criterion on effectiveness, whilst a study may meet this criterion (i.e. stating the source of effectiveness data), the quality of this data is not captured by the checklist. Without proper consideration of the quality and appropriateness of the evidence and methodology employed, the robustness of results obtained remains uncertain. To balance this concern, the quality of the data that was used in economic evaluations will be discussed following a review of the more general characteristics of analyses.
Ten countries were represented: 11 studies originated from the USA and seven from Canada. The remaining studies were from Germany, the UK, Australia, the Netherlands, Norway, France, Switzerland and Italy. One paper was published in French, which was translated by AP. Publications spanned 25 years, from 1989 to 2014.
Of the 38 papers accepted, most examined costs associated with screening strategies (n = 33); three reported costs associated with treatment for HH [55] [56] [57] , and single papers reported on hospital costs associated with HH [58] and financial implications of allogeneic use of HH blood donations [59] .
Screening
Of the 22 screening studies, most were quasi-experimental; and almost half (n = 14) employed some form of modelling. The quasi-experimental studies usually incorporated a cost-effectiveness analysis; most modelled studies used decision-modelling techniques, most commonly a simple decision tree (n = 11) [7, 8, 39, 44, [60] [61] [62] [63] [64] [65] [66] . In addition, three studies employed Markov modelling [32, 67, 68] . Other studies were a combination of quasi-experimental and cost description [69] [70] [71] [72] [42, [73] [74] [75] [76] [77] [78] [79] [80] [81] , quasi-experimental and cost analysis [82] . There were three non-experimental studies including a cost description [83] [84] [85] .
The economic perspective of the screening studies was reported as third-party payer in 48 % of studies [8, 32, 42, 61, 68, 69, 71, 73-75, 77, 79, 82, 84, 86, 87] ; service provider in 12 % [72, 76, 80, 81] ; societal [37, 67, 88] , government [39, 60, 65] and pathology laboratory [70, 78, 83] in 9 % each, and health system in 6% [7, 44] . Perspective was not evident in 6% [85, 89] . All screening papers reported direct costs only. Unit costs were sourced from government reimbursement rates in 19 % [7, 32, 42, 65, 68, 88] , national/local set/benchmarked prices [39, 44, 60, 70] or laboratory prices [77, 83, 88] in 9 % each, health insurance companies [74, 75] in 6 %, and hospital costs [63] , laboratory supplier [69] or from an organisation representing medical specialists [88] in 3 % each of studies. The source of cost data was not reported in 48 % (n = 16) [8, 61, 62, 64, 67, 71-73, 76, 78-82, 85, 89] .
The majority of studies that used decision-analysis methods (n = 14) modelled screening programmes over lifetime (71 %) [7, 8, 32, 61-64, 67, 68, 88] . A single modelled study had a time horizon of \1 year [39] , and in four modelling studies the time horizon was either unclear or not stated [44, 60, 65, 89] . Most quasi-experimental studies used a time horizon of B1 year [69-71, 73, 78, 79] , and single studies used a time horizon of two [42] , four [77] , five [82] and 11.5 years [75] , respectively. In four quasi-experimental studies the time horizon was not stated [72, 74, 76, 80] . Of the three non-experimental studies, two used a time horizon of 1 year or less [83, 85] and one study did not report on this [84] .
Discount rates were reported in 46 % of studies in which this was applicable, most commonly 3 % annually [55, 61-63, 68, 88] . These studies originated from the USA [63, 88] , Canada [8, 61, 62] and Germany [68] . A second German study employed differential discounting, using 5 % for costs and 0 % for effectiveness [64] . No discounting of costs or consequences was reported in 46 % of screening studies, which may have methodologically benefitted from this [7, 32, 39, 60, 75, 84] . The remaining studies did not discount costs or consequences as the time frame of the study did not warrant this, i.e. less than 12 months' time horizon.
Treatment and Other Economic Papers
Five studies were identified that reported other economic aspects of HH. All studies reported direct costs only, with the exception of Rombout-Sestrienkova, who reported both direct and indirect costs [55] . Two of the treatment papers reported on studies of a duration greater than 1 year [55, 57] and the third study did not provide a time frame. No treatment studies reported discounting costs or effects.
Studies compared costs between TV and erythrocytapheresis [55] , [57] , and erythrocytapheresis and erythropoietin in comparison with TV [56] . The latter was a case study of three patients, which provided clear details regarding the treatment regimen. Of the two studies comparing TV and erythrocytapheresis, one was an RCT with a well-defined protocol, which, whilst underpowered, provided a useful approach to compare treatment arms [55] . The final study was observational and had several methodological shortcomings which limited the validity of the findings [57] .
A further two papers were identified that examined other economic aspects related to HH. Gribble and colleagues examined the effect of a potential Food and Drug Administration (FDA) variation on use of HH donated blood for allogeneic purposes in the US [59] . Another study was identified that reported costs associated with hospitalisation of HH patients in an Australian jurisdiction [58] .
Methodological Assessment
The overall mean quality score of studies was 57.9 % (SD = 24.6). For screening studies, 11 were high quality (33 %), ten moderate quality (30 %) and 36 % (n = 12) were low quality. The mean quality score of the three treatment papers was 56.6 % (SD = 21.1), and the two papers reporting other economic aspects of HH returned a mean quality score of 47.0 % (SD = 12.0). Table 2 displays a summary of the study characteristics of the papers, with the full summary in the appendix. A large degree of heterogeneity between the studies was identified, in respect to estimates of prevalence, penetrance, uptake of screening, screening approaches, phenotypic thresholds, target populations, perspective of the economic analyses and country. Systematic reviews that identify studies with a large degree of heterogeneity should not involve a metaanalysis of the data [90] . A narrative synthesis was therefore undertaken, employing the approach outlined by Popay and colleagues [91] .
Synthesis of Results
Screening
Whilst the majority of studies reported both phenotypic and genotypic screening programmes to be cost effective, the evidence regarding effectiveness was of low quality in some studies. Effectiveness of screening programmes can be measured through uptake of screening amongst the target population, adherence to treatment and number of cases detected. These estimates are, in turn, dependent upon prevalence and penetrance estimates.
Both prevalence and penetrance estimates for HH are highly variable and difficult to precisely ascertain, which necessarily increases uncertainty in modelled studies. The modelled studies considered in this review used population prevalence estimates for C282Y homozygosity ranging between 0.2 and 0.7 % for persons of northern European heritage [7, 8, 32, 44, 60-65, 67, 68] . A small number of studies employed sensitivity analyses around prevalence estimates [7, 63, 68, 89] , which were similar to recent epidemiological estimates of C282Y homozygosity of between 0.44 and 0.68 % amongst persons of northern European heritage [11, 13] . Clinical penetrance rates were highly variable, in part due to different definitions of penetrance being employed. Regarding C282Y homozygotes, estimates for males ranged between 0.035 and 0.76 [7, 8, 32, 44, [60] [61] [62] [63] [64] [66] [67] [68] and for females between 0.28 and 0.32 [8, 44, [60] [61] [62] .
Uptake of population screening programmes was either not considered or considered to be absolute in almost all models [7, 8, 32, 44, [60] [61] [62] [63] [64] [65] [66] [67] . Where probability estimates of uptake of screening were reported, these varied considerably. Estimates were highest amongst voluntary blood donors (0.97) [80] , a workplace (0.85) [75] and a general Norwegian population (0.70) [42] . More conservative estimates were used for German health insurants (*0.003) [69] , and from a UK RCT (0.32) [39] . One study assumed the probability of interest in population screening to be 0.058, and of this group, an uptake rate of 0.805. Adherence to treatment was only considered in five modelled studies. Four of these used estimates of between 80 and 90 % [32, 61, 62, 64] , whilst a fifth used a more conservative estimate of 33 % [68] . According to the author of this latter study, the use of this lower estimate was based on the commonly used assumption of 50 % for adherence to drug treatment, and that a lower rate for more demanding interventions should be used.
The screening strategies that were examined included biochemical phenotype (serum ferritin, transferrin saturation, unsaturated iron binding capacity, alanine transaminase), biochemical phenotype with confirmatory liver biopsy, genotype and sequential (combination of both phenotype and genotype or different phases for biochemical tests). The approaches to screening varied considerably, particularly for biochemical investigations (see Table 3 ). Genotyping was used to confirm a diagnosis of HH in most studies published after 1999, i.e. following the identification of the HFE mutation [4] .
For iron studies, the cut-off points used to indicate iron overload and/or a diagnosis of HH varied: TfS for mixed cohorts ranged between C45 % and 60 % [39, 44, 65, 73, 74, 77, 78, 80, 92] , C50 % and 55 % for females [7, 8, 42, 61, 62, 71, 75, 76] and C55 % and 60 % for males [7, 8, 42, 61-63, 71, 75, 76, 79] . The cut-off points for SF were \110-300 lg/L for females [7, 8, 44, 71, 75, 82] ; 200-500 lg/L for males [7, 8, 71, 75, 79, 82] and 280-400 lg/L for a mixed cohort [77] . HFE genotyping was conducted for either C282Y [8, 44, 60, 64, 68, 69, 73, 76, 80, 89] or both C282Y and H63D mutations [7, 72, 78, 88, 93, 94] .
The heterogeneity of biochemical testing approaches makes comparison across studies not possible. Whilst TfS and SF were commonly used in economic evaluations of screening, investigators from the HEIRS study found that non-fasting and fasting TfS and SF were not ideally suited to this task [27] . Genotyping was included in most evaluations following the development of the test for the mutation of the HFE gene. In a systematic review, sensitivity of the C282Y genotype test was reported to range between 91.3 and 92.4 %, and specificity between 98.8 and Studies reported multiple screening strategies; sequential testing is carried out when the initial test result is elevated Gagne et al. [7] investigated 165 screening algorithms. Only the three most cost effective are included in this table
TfS transferrin saturation, SF serum ferritin, UIBC unsaturated iron binding capacity, SI serum iron, ALT alanine transaminase, TI transferrin index a The second stage of testing is conducted on the initial blood sample but in a different laboratory b One of these tests is conducted after fasting 100 % [44] , making this a more effective test for HH screening. Assumptions regarding prevalence, penetrance, sensitivity and specificity of tests, uptake of screening and adherence to treatment were highly variable across modelled studies, reflecting the paucity of robust data in the earlier years of economic analysis of HH-related interventions. However, more reliable probability estimates taken from epidemiological studies have improved the validity of recent CE models.
Utilities
All four of the cost-utility analysis studies on screening [8, 61, 62, 95] assigned utility weights for cirrhosis, diabetes, heart failure and/or combinations of these; however, the source of these weights was not stated. Adams and colleagues did not report the utility weight used for other states, i.e. homozygotes with no clinical symptoms of iron overload-related conditions [8, 61, 62] . Asberg and colleagues assumed a basal utility weight of 1.00 for all HH conditions, with the exception of cirrhotic patients, who were assigned a value of 0.95 [95] , notably higher than published elsewhere. Uhlig and colleagues reported a mean utility measure for the Norwegian population using the SF-6D of 0.803 [96] . Dan and colleagues measured the utilities of US patients with cirrhosis and reported a utility of 0.64 using the SF-6D [97] . Similarly, two studies by Adams and colleagues [8, 62] used utility values of 0.8 for symptoms of cirrhosis, 0.9 for diabetes and 0.5 for heart failure (the third study did not report the values used [61] ). In contrast to these estimates, Fryback and colleagues published utility population norms for the USA [98] . Using the SF-6D, mean population norms for persons aged 35-74 years ranged between 0.79 and 0.81, and using the EQ-5D, ranged between 0.87 and 0.89. This suggests that, with the possible exception of heart failure, Adams' estimated utility weights were higher than would be expected if participants' utility scores were measured directly; and the potential utility gains underestimated. Of note, none of the studies incorporated utility weights associated with arthritis. Adams and Speechley found that amongst a small sample of HH patients, arthritis strongly affected quality of life, more so than cirrhosis and diabetes [99] . Consequently, CUA studies that do not include utility weights associated with arthritis may be underestimating the impact this condition has on overall health associated with HH.
Treatment and Other Studies
This review identified three economic evaluations of HH treatment. Two of these studies concluded that TV was a more cost-effective strategy than erythrocytapheresis [55] and erythrocytapheresis plus erythropoietin [56] . The third study did not find double-erythrocytapheresis to be superior to TV from a cost perspective [57] .
Costs of other aspects of HH were assessed in two partial economic analyses. The first was a cost description study which assessed hospital costs [58] . The authors reported that between 2000 and 2006, disorders of iron metabolism cost US$2828 per admission (2007/08 US dollars).
The second study was a cost analysis assessing potential revenue earned from a policy variance allowing for red blood cell (RBC) product to be sourced from HH venesected blood [59] . When comparing loss of revenue from provision of free venepuncture services to HH patients with potential revenue from collection of RBC units, a favourable financial outcome was identified
Discussion
To date, this is the first comprehensive systematic review of health economic studies of all aspects of HH screening and treatment. To our knowledge, two other systematic reviews of health economic evidence and genetic screening have been conducted. The first assessed the economic evidence for screening a range of disorders, one of which was HH [100] . The second, due to inclusion and exclusion criteria, included just two studies [44] . Our current review critically appraises all full and partial economic evaluations of genetic and phenotypic screening programmes and treatment approaches for HH. A meta-analysis was not possible due to the high degree of heterogeneity between the studies.
Screening
Whilst almost all studies evaluating any form of screening programme in comparison with no screening concluded screening to be cost effective [32, 64, 67, 88] or cost saving [7, 8, [61] [62] [63] , methodological limitations undermine the robustness of these results. In cost-effectiveness studies the assessment of effectiveness is the crucial first step [52] . A paucity of effectiveness data (prevalence, penetrance, uptake of screening and adherence to treatment), particularly in studies conducted prior to 2000, contributed to the use of highly variable estimates in modelled studies. As the body of HH literature has grown considerably in the past decade, the quality of data used to populate economic models of HH interventions has improved.
In modelling studies using more than 150 algorithms, Gagne and colleagues found that clinical penetrance rates had a large effect on the assessment of cost effectiveness [7] . Penetrance rates are subject to more variability than prevalence, in part due to different definitions of penetrance: ranging from elevated iron studies to life-threatening co-morbidities related to iron overload. The European Assoication for the Study of the Liver (EASL) identified this inconsistency in 2000 and recommended use of four distinct categories of HH, ranging from genetic mutation only through to organ damage [29] . A recent Australian epidemiological study reported penetrance (including early symptoms such as arthritis of the metacarpophalangeal joints through to irreversible organ damage) as 28.4 % for males and 1.2 % for females [11] . Penetrance of cirrhosis amongst C282Y homozygotes has been reported by several studies, with estimates ranging between 2 % and 6 % [11, 38, 42] . Earlier studies included in this review used markedly higher rates for developing life-threatening disease manifestations (commonly described as cirrhosis and heart disease): 40-76 % for males and 28-32 % for females [8, 61, 62, 67] . More recent studies have used lower estimates ranging between 1.6 and 5.6 % [7, 68] that are in keeping with recent epidemiological data.
An important aspect to consider regarding economic implications of a large-scale screening programme is uptake of screening. Whilst many modelled studies did not consider this, so implicitly assumed 100 % uptake, amongst those that did, estimates were variable, as were the study populations considered. Amongst voluntary blood donors, an uptake rate of 97 % was used [80] , 85 % for a USA workplace [75] and 70 % for the general population of a Norwegian county [42] . These latter two studies used estimates based on clinical studies in which a broad range of health interventions were offered, not just HH screening. It is likely that this broad range of interventions enhanced uptake more so than if HH screening was offered on its own. In support of this, far lower rates were reported for German health insurants (0.3 %) [69] and from a UK general practice setting (32 %) [39] for HH-only screening. One study assumed a probability of interest in screening for the German male population screening of 5.8 %, and of this group, an uptake rate of 80.5 % [68] .
Adherence to treatment is another important aspect of the cost effectiveness of HH screening programmes. Both treatment costs and disease-related costs when treatment is not adhered to impact significantly on effectiveness and long-term costs [68] . Of the five studies that considered adherence, four of these used estimates of between 80 and 90 % [32, 61, 62] , and the fifth used an estimate of 33 % [68] . This latter estimate was based on the commonly used assumption of 50 % for adherence to drug treatment, and that a lower rate for more demanding interventions should be used [68] . In addition, a longitudinal study of HH treatment noted a linear decrease in adherence from 80 to 33 % by year nine [46] . This suggests that the assumptions regarding adherence in earlier studies was highly optimistic, potentially increasing the cost effectiveness of screening interventions.
Whilst assumptions are necessary when calculating the cost effectiveness of HH screening programmes, these have generated uncertainty regarding the findings. This is understandably more of an issue amongst studies that were conducted when little data was available regarding key parameters. However, of the more recent studies published, Rogowski's economic analysis was the only one to be based on an objective assessment of the effectiveness of screening. Many of the studies contained in this review, particularly the early studies, contain assumptions that cannot be supported and may lead to incorrect conclusions being drawn as to the cost effectiveness of screening.
Almost all of the modelled studies employed decisionanalysis techniques using decision trees, with short timehorizons (i.e 1 year or less). The nature of HH, whether treated or not, is one which affects the patient for their lifetime, therefore to fully capture the costs and effects, models should ideally be conducted over a lifetime. Further, models would use probabilistic decision analysis to incorporate uncertainty of key parameters, and Markov modelling to capture long-term costs and effects. Just one paper did this [68] , and two used decision trees and Markov modelling [32, 67] .
Whilst targeted screening of individuals at high risk of HH and iron overload (i.e. offspring and siblings of HH probands) has been adopted by many governments and is viewed as a cost effective approach, questions remain regarding the cost effectiveness of population screening. In the current review, just one paper was identified that reported population screening to be not cost effective [68] . This study by Rogowski was of very high quality according to the BMJ checklist, and is the highest quality costeffectiveness study of HH screening to date.
Rogowski's modelled study aimed to calculate the cost effectiveness of three screening strategies (genotypic, phenotypic and sequential) for the German Caucasian male population aged 30 years and male offspring of HH probands. This model assumed that genetically HH positive people ''with elevated serum iron values would be offered phlebotomies; [and] annual serum iron testing would be offered to all others''. Rogowski does not provide a definition of 'elevated' serum iron values, which is in keeping with the EASL guidelines. These guidelines make note of the fact that internationally, recommendations regarding commencement of TV are based on empirical evidence, making it unclear when treatment should commence. Different cut-off points indicative of iron overload and the consequential need for treatment will necessarily alter the number of participants requiring treatment, and therefore the costs associated with the strategy. Again in accordance with EASL guidelines, the study assumed annual SF monitoring for C282Y homozygotes who do not have elevated serum iron levels at the time of diagnosis. The study concluded that targeted sequential screening of male offspring was the most cost-effective strategy.
Annual SF monitoring for C282Y homozygotes who do not have elevated serum iron levels at the time of diagnosis, whilst in accordance with EASL guidelines, is not a universal strategy. For example, countries such as Australia recommend retesting every 2-5 years [15] . Further, Adams and Barton note longitudinal studies of patients with HH suggest that many HH probands will not develop iron overload, thereby rendering annual iron studies excessive [101] . As such, there may be an overestimation of costs in the screening arm of Rogowski's model and the impact of alternative strategies is appropriate.
Utilities
Another aspect of economic evaluations that requires further attention in the future is the utility weights included. To date, no studies have used reliable utility weights when conducting cost-utility analyses of HH screening programmes. The four studies identified in this review used estimates of unknown source that were likely to be higher than expected if measured directly from a sample of HH patients [8, 32, 61, 62] . Potential utility gains could be grossly underestimated. More research investigating utility weights for the various stages of HH would contribute to more robust cost-utility analyses.
The HSUVs incorporated into the economic evaluations reviewed focused on cirrhosis, type 2 diabetes and heart disease. Other health conditions/states, such as fatigue and arthritis, were not considered. In part, this may have been due to uncertainty surrounding the aetiology and the subjective measurement of these conditions. However, relatively high rates of HH-related osteoarthritis have been reported [102] [103] [104] , and quality of life amongst HH patients has been found to be more negatively impacted upon by arthritis than cirrhosis or diabetes [99] . Therefore, ignoring utility estimates related to arthritis may underestimate utility gains from HH interventions. With care, HSUV for a range of health states related to HH should be included in cost-utility analyses, with the net effect of multiple morbidities preferably captured via a validated multi-attribute utility instrument.
The penetrance estimates used in Adams' three studies for life-threatening conditions (heart failure, cirrhosis, hepatocellular carcinoma and diabetes) were 0.43 for males and 0.28 for females. Asberg and colleagues (2002) defined penetrance as cirrhosis, and used a probability estimate of 0.049. The estimates used by Adams and colleagues are higher than found in recent epidemiological data, noted above, whereas Asberg et al.'s is within the range reported. Adam et al.'s utility estimates for each condition were found to be higher for most conditions than reported in the literature [105] [106] [107] , as were the penetrance estimates. The use of these inflated estimates is likely to lead to incorrect results. Whilst Asberg et al. used a penetrance estimate that was in keeping with recent epidemiological data, which ranges between 0.02 and 0.06 [11, 38, 42] , the utility score of 0.95 assigned to this state is notably higher than reported for non-HH patients with cirrhosis (ranging between 0.67 and 0.75) [105] .
One of the strengths of this review was there were no limitations on language or date of publication. Although a meta-analysis was not possible, it is clear that whilst most full economic evaluations reported HH screening programmes to be cost effective or cost saving, there were methodological limitations in these studies that impact the robustness of the findings. Further rigorous, full economic evaluations are required to resolve some of the controversies regarding the economic aspects of screening programmes. More robust modelling, incorporating a more complete understanding of the costs associated with HH and accurate utility weights, will make a valuable contribution to this debate.
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